Prenetics Global Ltd (PRE) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Prenetics Global Ltd stock (PRE) is currently trading at $21.56. Prenetics Global Ltd PS ratio (Price-to-Sales) is 3.91. Analyst consensus price target for PRE is $31.67. WallStSmart rates PRE as Sell.
- PRE PE ratio analysis and historical PE chart
- PRE PS ratio (Price-to-Sales) history and trend
- PRE intrinsic value — DCF, Graham Number, EPV models
- PRE stock price prediction 2025 2026 2027 2028 2029 2030
- PRE fair value vs current price
- PRE insider transactions and insider buying
- Is PRE undervalued or overvalued?
- Prenetics Global Ltd financial analysis — revenue, earnings, cash flow
- PRE Piotroski F-Score and Altman Z-Score
- PRE analyst price target and Smart Rating
Prenetics Global
📊 No data available
Try selecting a different time range
Smart Analysis
Prenetics Global Ltd (PRE) · 8 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/book, revenue growth. Concerns around return on equity and operating margin. Significant fundamental concerns warrant caution or avoidance.
Prenetics Global Ltd (PRE) Key Strengths (2)
Revenue surging 248.60% year-over-year
Trading at 1.90x book value, attractively priced
Supporting Valuation Data
Prenetics Global Ltd (PRE) Areas to Watch (6)
Company is destroying shareholder value
Losing money on operations
Company is losing money with a negative profit margin
Very low institutional interest at 13.95%
Small-cap company with higher risk but more growth potential
Revenue is fairly priced at 3.91x sales
Prenetics Global Ltd (PRE) Detailed Analysis Report
Overall Assessment
This company scores 33/100 in our Smart Analysis, earning a F grade. Out of 8 metrics analyzed, 2 register as strengths (avg 9.0/10) while 6 fall into concern territory (avg 2.2/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Revenue Growth, Price/Book. Valuation metrics including Price/Book (1.90) suggest the stock is attractively priced. Growth metrics are encouraging with Revenue Growth at 248.60%.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Profit Margin. Some valuation metrics including Price/Sales (3.91) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -31.80%, Operating Margin at -33.30%, Profit Margin at -63.10%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -31.80% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 248.60% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
PRE Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
PRE's Price-to-Sales ratio of 3.91x sits near its historical average of 3.49x (86th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 0% below its historical high of 3.91x set in Mar 2026, and 40% above its historical low of 2.8x in Mar 2026. Over the past 12 months, the PS ratio has expanded from ~3.1x, reflecting growing market expectations outpacing revenue growth.
WallStSmart Analysis Synopsis
Data-driven financial summary for Prenetics Global Ltd (PRE) · HEALTHCARE › DIAGNOSTICS & RESEARCH
The Big Picture
Prenetics Global Ltd is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 92M with 249% growth year-over-year. The company is currently unprofitable, posting a -63.1% profit margin.
Key Findings
Revenue growing at 249% YoY, reaching 92M. This pace significantly outperforms most DIAGNOSTICS & RESEARCH peers.
The company is unprofitable with a -63.1% profit margin. The path to breakeven will be the key catalyst.
Free cash flow is -22M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Growth sustainability: can Prenetics Global Ltd maintain 249%+ revenue growth, or will competition slow it down?
Sector dynamics: monitor DIAGNOSTICS & RESEARCH industry trends, competitive moves, and regulatory changes that could impact Prenetics Global Ltd.
Bottom Line
Prenetics Global Ltd is a high-conviction growth story with revenue accelerating at 249% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin -63.1% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Data sourced from SEC Form 4 filings
Last updated: 10:04:31 AM
About Prenetics Global Ltd(PRE)
NASDAQ
HEALTHCARE
DIAGNOSTICS & RESEARCH
USA
Prenetics Global Ltd (PRE) is a leading health technology innovator specializing in genetic and diagnostic testing, leveraging advanced technologies to provide essential health insights for consumers and healthcare professionals alike. The company boasts a comprehensive portfolio of cutting-edge genetic testing solutions and integrated digital health services, driving its robust international growth through strategic partnerships and an unwavering dedication to research and development. Positioned at the forefront of personalized medicine, Prenetics is well-equipped to meet the growing consumer demand for accessible and actionable health information, making it a compelling investment opportunity in the rapidly evolving healthcare sector.